Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia : a worldwide cross-sectional study
Authors:ID Elshorbagy, Amany (Author)
ID Lyons, Alexander R.M. (Author)
ID Vallejo-Vaz, Antonio J. (Author)
ID Stevens, Christophe A. T. (Author)
ID Dharmayat, Kanika I. (Author)
ID Brandts, Julia M. (Author)
ID Catapano, Alberico L. (Author)
ID Freiberger, Tomas (Author)
ID Hovingh, G. Kees (Author)
ID Mata, Pedro (Author)
ID Grošelj, Urh (Author)
ID Battelino, Tadej (Research coworker)
ID Cevc, Matija (Research coworker)
ID Debeljak, Maruša (Research coworker)
ID Drole Torkar, Ana (Research coworker)
ID Fras, Zlatko (Research coworker)
ID Jug, Borut (Research coworker)
ID Čugalj Kern, Barbara (Research coworker)
ID Kovač, Jernej (Research coworker)
ID Mlinarič, Matej (Research coworker)
ID Šikonja, Jaka (Research coworker), et al.
Files:.pdf PDF - Presentation file, download (857,07 KB)
MD5: F688CF3F0AF49E422D2BE4E2BC273A11
 
URL URL - Source URL, visit https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00221-3/fulltext
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Background Statins are the cornerstone treatment for patients with heterozygous familial hypercholesterolaemia but research suggests it could increase the risk of type 2 diabetes in the general population. A low prevalence of type 2 diabetes was reported in some familial hypercholesterolaemia cohorts, raising the question of whether these patients are protected against type 2 diabetes. Obesity is a well known risk factor for the development of type 2 diabetes. We aimed to investigate the associations of known key determinants of type 2 diabetes with its prevalence in people with heterozygous familial hypercholesterolaemia. Methods This worldwide cross-sectional study used individual-level data from the EAS FHSC registry and included adults older than 18 years with a clinical or genetic diagnosis of heterozygous familial hypercholesterolaemia who had data available on age, BMI, and diabetes status. Those with known or suspected homozygous familial hypercholesterolaemia and type 1 diabetes were excluded. The main outcome was prevalence of type 2 diabetes overall and by WHO region, and in relation to obesity (BMI ≥30∙0 kg/m²) and lipid-lowering medication as predictors. The study population was divided into 12 risk categories based on age (tertiles), obesity, and receiving statins, and the risk of type 2 diabetes was investigated using logistic regression. Findings Among 46 683 adults with individual-level data in the FHSC registry, 24 784 with heterozygous familial hypercholesterolaemia were included in the analysis from 44 countries. 19 818 (80%) had a genetically confirmed diagnosis of heterozygous familial hypercholesterolaemia. Type 2 diabetes prevalence in the total population was 5·7% (1415 of 24 784), with 4·1% (817 of 19 818) in the genetically diagnosed cohort. Higher prevalence of type 2 diabetes was observed in the Eastern Mediterranean (58 [29·9%] of 194), South-East Asia and Western Pacific (214 [12·0%] of 1785), and the Americas (166 [8·5%] of 1955) than in Europe (excluding the Netherlands; 527 [8·0%] of 6579). Advancing age, a higher BMI category (obesity and overweight), and use of lipid-lowering medication were associated with a higher risk of type 2 diabetes, independent of sex and LDL cholesterol. Among the 12 risk categories, the probability of developing type 2 diabetes was higher in people in the highest risk category (aged 55–98 years, with obesity, and receiving statins; OR 74∙42 [95% CI 47∙04–117∙73]) than in those in the lowest risk category (aged 18–38 years, without obesity, and not receiving statins). Those who did not have obesity, even if they were in the upper age tertile and receiving statins, had lower risk of type 2 diabetes (OR 24∙42 [15∙57–38∙31]). The corresponding results in the genetically diagnosed cohort were OR 65∙04 (40∙67–104∙02) for those with obesity in the highest risk category and OR 20∙07 (12∙73–31∙65) for those without obesity. Interpretation Adults with heterozygous familial hypercholesterolaemia in most WHO regions have a higher type 2 diabetes prevalence than in Europe. Obesity markedly increases the risk of diabetes associated with age and use of statins in these patients. Our results suggest that heterozygous familial hypercholesterolaemia does not protect against type 2 diabetes, hence managing obesity is essential to reduce type 2 diabetes in this patient population
Keywords:Diabetes Mellitus, type 2, aged, risk factors, cross-sectional studies, sladkorna bolezen, tip 2, starostniki, dejavniki tveganja, presečne študije
Publication status:Published
Publication version:Version of Record
Year of publishing:2024
Number of pages:str. 811-823
Numbering:Vol. 12, iss. 11
PID:20.500.12556/DiRROS-30042 New window
UDC:616.379
ISSN on article:2213-8587
DOI:10.1016/S2213-8587(24)00221-3 New window
COBISS.SI-ID:211828227 New window
Publication date in DiRROS:12.06.2026
Views:48
Downloads:30
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:The Lancet : Diabetes & Endocrinology
Publisher:Elsevier
ISSN:2213-8587
COBISS.SI-ID:1636780 New window

Document is financed by a project

Funder:Other - Other funder or multiple funders
Funding programme:Imperial College of London
Project number:-
Name:Imperial College London
Acronym:-

Funder:Other - Other funder or multiple funders
Funding programme:Pfizer Independent Grant for Learning & Chang
Project number:16157823
Name:-

Funder:Other - Other funder or multiple funders
Funding programme:Amgen
Project number:/
Name:/

Funder:Other - Other funder or multiple funders
Funding programme:MSD
Project number:/
Name:/
Acronym:/

Funder:Other - Other funder or multiple funders
Funding programme:Sanofi-Aventis
Project number:/
Name:/

Funder:Other - Other funder or multiple funders
Funding programme:Daiichi-Sankyo
Project number:/
Name:/

Funder:Other - Other funder or multiple funders
Funding programme:Regeneron
Project number:/
Name:/

Funder:Other - Other funder or multiple funders
Funding programme:National Institute for Health Research
Project number:NIHR
Name:Applied Research Collaboration Northwest London

Funder:Other - Other funder or multiple funders
Funding programme:National Institute for Health Research, Biomedical Research Centre
Project number:NIHR BRC
Name:National Institute for Health Research, Biomedical Research Centre
Acronym:NIHR BRC

Funder:Other - Other funder or multiple funders
Project number:/
Name:Beatriz Galindo
Acronym:NIHR

Funder:Other - Other funder or multiple funders
Funding programme:Austrian Heart Foundation
Project number:/
Name:-

Funder:Other - Other funder or multiple funders
Funding programme:Tyrolean Regional Government
Project number:/
Name:-

Funder:Other - Other funder or multiple funders
Funding programme:Ministry of Health
Project number:/
Name:Ricerca Corrente

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Back